SCHEQ (STEMM & Cancer Health Equity) Founder and CEO, Dr. Eugene Manley, Jr., and NYU Langone’s Dr. Joshua Sabari, were interviewed by Lisa Hatfield at the Patient Empowerment Network (PEN) as part of the [ACT]IVATED Non-Small Cell Lung Cancer (NSCLC) Program. Their specific program was [ACT]ivated NSCLC Biomarkers, where they provide key takeaways for patients. They discussed disparities in biomarkers and biomarker testing, community engagement, precision medicine, partnerships, and clinical trials. Our session was broken down into several sessions and the link to the videos and excerpts are provided below.
- Biobanks and patient databases. https://powerfulpatients.org/2024/05/02/how-can-we-leverage-lung-cancer-biomarker-data-to-address-health-disparities/
- How precision medicine can reduce biomarker disparities. https://powerfulpatients.org/2024/05/02/lung-cancer-biomarker-disparities-how-precision-medicine-and-research-can-help/
- Role of partnerships between researchers, providers, community organizations, and policy makers to address disparities. https://powerfulpatients.org/2024/05/02/maximizing-biomarker-equity-leveraging-partnerships-to-close-biomarker-disparities-in-lung-cancer/
- Interventions or advocacy to reduce biomarker disparities. https://powerfulpatients.org/2024/05/02/equity-in-action-addressing-biomarker-disparities-in-lung-cancer/
